Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. - Wikidata - awgldk - TriplyDB

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

http://www.wikidata.org/entity/Q34037065

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors Glomerular diseases and cancer: evaluation of underlying malignancy.Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F New Therapeutic Approaches in Polycythemia Vera Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations Management of polycythaemia vera: a critical review of current data.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Ruxolitinib: A Review in Polycythaemia Vera.Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.Experience with ruxolitinib in the treatment of polycythaemia vera.Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Polycythemia Vera Management and Challenges in the Community Health Setting.β-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis.Current and future treatment options for polycythemia vera.Mechanisms of thrombogenesis in polycythemia vera Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon.Novel and emerging therapies for the treatment of polycythemia vera A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database.Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia Diagnosis and Management of Polycythemia Vera in a Ferret (Mustela putorius furo).From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Rethinking the diagnostic criteria of polycythemia vera.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Epidemiology of MPN: what do we know?Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Quality of life in MPN comes of age as a therapeutic target.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.

P2860

Q26738514-66C8FC2E-C0CD-4585-85DF-F6B20979C23C Q26750696-22EE6239-78E5-4797-BDE5-744DC72091A6 Q26766319-71D452CA-A8AF-4DA3-86A3-190FF7DF2523 Q26772881-8437FFC9-364F-4FD4-AC09-9E319B2D105D Q26777265-0433466E-2403-410C-9E18-F7B4A4B447EC Q26779686-695EE186-7207-496C-890C-B5A8A8CB8C84 Q26795666-FD07682F-EB04-4D49-9CEA-71C0A6DBBF72 Q26795677-F3B04105-84A0-4841-952D-E50347741DDC Q26851894-6EC83027-5FA6-4560-A7CB-F714986A1E8F Q28078404-E986A9A1-2505-44EC-81D6-2C9BB0FC9F51 Q31009757-08714BD5-3907-4902-99E3-84B05B722EF8 Q33420037-DA0BCD48-69C7-4967-9CFE-CB9509F71290 Q33425781-83EE2861-4C08-4031-9210-4D910E4BD19C Q33434734-06C9BDCA-B08B-4EE6-9EDB-4E6BBDBCAC01 Q33605624-DC63CDFF-A832-41DC-902B-7D8CF1EE0547 Q33747797-9FB9B09F-B026-40E9-846B-1E5E2242A0A5 Q33803036-601DF7C4-C403-4897-AB1D-BE8DFB1BC990 Q33853100-3C6E050C-D8D0-4319-A903-E9AAF2539D7C Q35572748-2C1F7F1A-D2EE-4454-A5F0-8133CB81DE73 Q35738656-ED4DFC05-6224-4252-BE3E-AF4E1FEA4E6B Q35938283-38FB7382-91CA-4500-A35C-35E23B9C9D1E Q36150377-32A64681-D77B-4C02-BA6A-880B1AFD1858 Q36266377-01A3AE78-3A8F-4845-AE20-D7917CE35740 Q36529881-DC38D069-8CD1-472D-961D-254429542746 Q36782943-E6999670-8FE5-4A8C-8E1D-80BCBCB2E2A0 Q36814056-B577639A-5BC1-4CC3-A8AB-2F066A3397E4 Q37048533-3A4D2032-6BB2-4A42-9DB4-8AADAAC9B152 Q37069633-3C5E440A-8B8A-41D1-A8D8-3FC87F1BF01E Q37092415-577A53AC-D79A-4B7D-836D-B93D74FF93B7 Q37153294-2F2F6975-21AF-4A73-8664-A14A5121CABA Q37505883-67E83B27-B7AE-4D00-ACA6-FD1BCE51D77D Q37555790-9BBF8908-EEAA-4F51-8B12-89F824191958 Q37631854-F1E686DA-06C5-46D2-A712-E4BE2FE2FD7F Q37679175-0BBDB135-F507-4EA1-9A0A-9BBAFA287B10 Q38172388-7EA1720A-7D65-46F0-AB88-DF5F4CE88E34 Q38210664-AD6827A7-66AB-4FE0-AEEE-8F3ED8AD8F0A Q38240406-8BC6D469-17C7-436E-A4DF-6A3A3797244F Q38242725-DC05AB97-63F4-4294-83D8-A6B0A536D3E8 Q38254893-07101DA6-AA2F-4286-8223-02309074F80F Q38255717-8FA0499F-C695-44ED-973E-825D82E344F9

P2860

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

http://www.wikidata.org/entity/Q34037065

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Survival and prognosis among 1 ...... vera: an international study.

@ast

Survival and prognosis among 1 ...... vera: an international study.

@en

Survival and prognosis among 1 ...... vera: an international study.

@nl

type

label

Survival and prognosis among 1 ...... vera: an international study.

@ast

Survival and prognosis among 1 ...... vera: an international study.

@en

Survival and prognosis among 1 ...... vera: an international study.

@nl

prefLabel

Survival and prognosis among 1 ...... vera: an international study.

@ast

Survival and prognosis among 1 ...... vera: an international study.

@en

Survival and prognosis among 1 ...... vera: an international study.

@nl

P1433

Q34037065-5B4A680F-D006-4128-9B7F-2C50B48678F1

P1476

Q34037065-D9FAFC4C-46F2-459B-A064-E78AD3DC96A5

P2093

Q34037065-0A10A284-6DAF-43C4-A72C-CB5D69E1CC68

Q34037065-17B8CDEE-C4F9-4CF7-A1F8-4C9699F09B82

Q34037065-20686DAF-3C40-4BFE-8F41-9609E546740E

Q34037065-358CAD2E-A209-49EE-8584-EBDB13D9A933

Q34037065-37EE154C-0558-4F07-B8CF-2499D6D14990

Q34037065-3927EEAC-4AAA-4BAD-A0F3-E4133404E82E

Q34037065-43944F3D-92A2-4CD4-8F31-F91ED8D64F96

Q34037065-5C68C851-E886-4589-906F-2930862FB168

Q34037065-5E09DF44-C11A-4A2E-AAC3-986D50DE6C14

Q34037065-743787B0-E172-45C1-AAFF-10D7231D30A2

P2860

Q34037065-03E0C127-DC89-4397-99AD-5299A8057F67

Q34037065-09863A3F-9B46-4E23-8A76-17AE2F946F28

Q34037065-2CE803A3-E3A6-4943-99F8-631A9A06BC9C

Q34037065-3E982973-BD6A-43B4-B19E-D0E2E746A140

Q34037065-4FD086E7-2CF7-44BE-80AF-930323FEE505

Q34037065-527BB97E-D4B1-4C64-B606-FFEB1CD3FD2D

Q34037065-5C7A56F4-6B87-4F4A-A96D-629E818063E0

Q34037065-6025F6AA-A8B6-4824-8E22-C276E4645539

Q34037065-698D7B2E-3D0E-4C88-B5D0-8C9DC60883CD

Q34037065-74943904-086B-43A5-A4CF-09E1AEBD14E7

P2888

Q34037065-D7752BCB-5A6A-4C7B-8232-7DCD8BFE87E0

P304

Q34037065-7C8DC207-EEBB-4BF8-A727-ED879B9AE10F

P31

Q34037065-FBF96C58-E424-483A-AEEA-B43F03A15858

P356

Q34037065-53C50BD6-3238-44DB-BB0A-D4CD6954431B

P433

Q34037065-0C0F3160-EC14-4FCC-8F19-8B4C763D7E03

P478

Q34037065-60E785E6-F114-42CA-B94B-53AEA23D7549

P50

Q34037065-E864C19B-9752-473F-B4A5-452E93EB41FD

P577

Q34037065-3FA644E8-CC5E-4619-9FF3-F6AA75CDCC61

P5875

Q34037065-0B86D9F1-7FC3-495A-B309-A456C61A877A

P6179

Q34037065-3DAF1121-5092-4E9F-9F81-699047426232

P698

Q34037065-352F787B-F00A-4470-AA17-3F5F5D8F8052

P921

Q34037065-CA2360F0-5D90-4498-85AF-144DAEA61BE9

P932

Q34037065-AAB73584-BB73-41A5-A190-7DDD44D4F422

P356

P1433

P1476

Survival and prognosis among 1 ...... vera: an international study.

@en

P2093

A Carobbio

http://www.w3.org/2001/XMLSchema#string

A M Vannucchi

http://www.w3.org/2001/XMLSchema#string

A Pardanani

http://www.w3.org/2001/XMLSchema#string

A Rambaldi

http://www.w3.org/2001/XMLSchema#string

B Gisslinger

http://www.w3.org/2001/XMLSchema#string

D R Larson

http://www.w3.org/2001/XMLSchema#string

E Rumi

http://www.w3.org/2001/XMLSchema#string

F Passamonti

http://www.w3.org/2001/XMLSchema#string

F Rodeghiero

http://www.w3.org/2001/XMLSchema#string

G Finazzi

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Personalized management of essential thrombocythemia-application of recent evidence to clinical practice

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Clinical effect of point mutations in myelodysplastic syndromes

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Polycythemia vera: stem-cell and probable clonal origin of the disease.

P2888

P304

1874-1881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.163

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237059214

http://www.w3.org/2001/XMLSchema#string

P6179

1012891967

http://www.w3.org/2001/XMLSchema#string

P698

23739289

http://www.w3.org/2001/XMLSchema#string

P921

P932

3768558

http://www.w3.org/2001/XMLSchema#string